This Study Will Evaluate if the Field Force Pulsed Field Ablation System is Safe and Effective for Treating Sustained Monomorphic Ventricular Tachycardia, a Potentially Serious Fast Heart Rhythm of the Heart. The Treatment Uses Short Pulses of Energy to Target and Destroy the Heart Tissue Causing VT
Pivotal Study to Evaluate Catheter Ablation in Patients With Scar-Related Monomorphic Sustained VT in the Ventricular Ectopy and Reduction in Tachycardia Ablation Studies Program (VERITAS SCAR VT)
The VERITAS VT Study is a prospective, multicenter, international, single-arm clinical investigation designed to evaluate the safety and effectiveness of the FieldForce™ Pulsed Field Ablation System for the treatment of sustained monomorphic ventricular tachycardia (VT). Eligible patients undergoing catheter ablation for VT will receive treatment with the investigational pulsed field ablation system according to the study protocol.
The study will assess acute and chronic outcomes including major adverse events, freedom from recurrent ventricular tachycardia, need for antiarrhythmic drug escalation, repeat ablation procedures, and other clinically relevant outcomes through 180 days following the index ablation procedure.
調査の概要
状態
詳細な説明
Ventricular tachycardia remains a significant source of morbidity and mortality among patients with structural heart disease. Although catheter ablation is an established therapeutic option, long-term recurrence rates remain substantial and procedural challenges continue to exist.
The VERITAS VT Study is a prospective, multicenter, single-arm clinical investigation evaluating the safety and effectiveness of the Field Force Pulsed Field Ablation System in subjects with sustained monomorphic ventricular tachycardia. Eligible participants will undergo mapping and ablation using the Field Force Pulsed Field Ablation System during the index procedure. Subjects will be followed for 180 days after the index procedure to assess safety and effectiveness outcomes.
The primary safety objective is to evaluate the incidence of device- and procedure-related major adverse events. The primary effectiveness objective is to evaluate freedom from recurrence of sustained monomorphic ventricular tachycardia through 180 days following the index ablation procedure
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Philippa Hill
- 電話番号:+1 (909)-287-9659
- メール:hill@fieldmedicalinc.com
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Signed patient informed consent form (ICF).
- Female and male patients aged ≥ 18 and ≤ 85 years.
- Implantable Cardioverter-Defibrillator (ICD) implanted ≥ 180 days prior to enrollment.
Clinically Indicated for ventricular tachycardia (VT) ablation by 2019 guidelines:
- At least one (1) episode of VT, defined as continuous VT lasting > 30 seconds or requiring termination due to hemodynamic compromise, detected by an implanted ICD ≤ 180 days prior to enrollment and
- Refractory to, contraindicated or intolerant of at least one (1) Class I or III Antiarrhythmic Drug (AAD)
Sustained scar-related monomorphic ventricular tachycardia (MMVT):
- Objective evidence of ventricular scar confirmed by imaging (magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), intracardiac echocardiography/ transesophageal echocardiogram (ICE/TEE) and/or electro anatomical mapping (EAM)) Or
- Prior myocardial infarction (MI)
- Left ventricular ejection fraction (LVEF) ≥ 20% confirmed by echocardiography or comparable imaging techniques within 180 days prior to enrollment or during baseline evaluation.
Exclusion Criteria:
Subjects will be excluded if ANY of the following apply:
- VT secondary to reversible causes (e.g. electrolyte abnormalities, drug or alcohol-induced arrhythmia or non-cardiac cause).
- VT ablation within 14 days prior to enrollment.
- Greater than three (3) VT ablations within one (1) year prior to enrollment.
- Ventricular fibrillation (VF), polymorphic VT or Torsades de Pointes (TdP) as primary clinical arrhythmia.
- Bundle branch reentry (BBR), Idiopathic, Para-Hisian or Fascicular VT.
For non-ischemic cardiomyopathy (NICM) if the following apply:
- Active (within 120 days) inflammatory process (e.g. myocarditis)
- Sarcoidosis
- Hypertrophic cardiomyopathy (HCM)
- Laminopathy (LMNA-related cardiomyopathy)
- Brugada syndrome (BrS)
- Amyloidosis
- Acute myocardial infarction ≤ 90 days prior to enrollment.
- Recent cardiac intervention ≤ 90 days prior to enrollment including but not limited to Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft (CABG), lead revision or upgrade, etc.
- Implanted with a ventricular assist device (VAD).
- Severe mitral or aortic regurgitation or stenosis evaluated by echo or comparable technique.
- Presence of an aortic or mitral mechanical valve.
- New York Heart Association (NYHA) Class IV heart failure.
- Uncontrolled abnormal bleeding and/or clotting disorder.
- Contraindication to systemic or oral anticoagulation.
- Presence of active intracardiac thrombus detected by imaging (pre-procedural via transesophageal echocardiogram (TEE) or transthoracic echocardiogram (TTE), CT, MRI, or intra-procedural via intracardiac echocardiography (ICE).
- Ineligible for ablation according to physician judgement (including but not limited to hemodynamically unstable, prior interatrial patch, Amplatzer, etc.).
- Serious or untreated medical conditions that would prevent participation in the study interfere with assessment or therapy, or confound data or its interpretation, including but not limited to solid organ or hematologic transplant, or currently being evaluated for an organ transplant.
- Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or significant dyspnea at the time of enrollment.
- Body Mass Index ≥ 40.
- Chronic renal insufficiency of estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2.
- Active malignancy.
- Active systemic infection.
- Life expectancy is less than one year.
- Prohibitively distorted cardiac anatomy due to congenital heart disease.
- Participation in another investigational study that may interfere with the procedure outcomes for this study unless pre-approved by sponsor.
- Unable to understand the nature of this study or is unwilling or unable to attend all the study visits.
- Pregnancy or planned pregnancy, lactating or any women of childbearing potential who is not on a reliable form of birth control.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Field Force Pulsed Fiel Ablation
Participants will undergo ventricular tachycardia ablation using the Field Force Pulsed Field Ablation System during the index procedure.
|
The Field Force Pulsed Field Ablation System is an investigational device that delivers non-thermal pulsed electric field energy through a catheter-based platform to ablate targeted cardiac tissue.
The system is intended for use during catheter ablation procedures in patients with sustained monomorphic ventricular tachycardia (VT) to treat tissue involved in the initiation and maintenance of the arrhythmia.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Primary Safety Endpoint - Freedom from casual or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure. (Or within 90 days for esophageal events (fistula/perforation)
時間枠:As applicable within 7 days or 90 days after the index ablation procedure
|
A pre-defined list of device - or procedure-related MAEs, as adjudicated by the Clinical Events Committee (CEC), occurring within 7 days after the index ablation procedure (or within 3 months after the index ablation procedure for any esophago-pericardial fistula/esophageal perforation) will be considered a primary safety event
|
As applicable within 7 days or 90 days after the index ablation procedure
|
|
Primary Effectiveness: Freedom from recurrence of sustained monomorphic VT
時間枠:Through 6 months most the index ablation procedure
|
Freedom from recurrence of sustained monomorphic VT (MMVT) in the absence of new or increased dose of Class I or III antiarrhythmic drugs (AAD) for any ventricular arrhythmia through 6 months after the index ablation procedure
|
Through 6 months most the index ablation procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Secondary Effectiveness Endpoint: Percentage of patients with reduced ventricular tachycardia burden
時間枠:6 months post index procedure
|
Percentage of patients with reduced ventricular tachycardia burden
|
6 months post index procedure
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Vivek Reddy, MD、Mount Sinai Hospital
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- CLN-00011
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。